CAS: 870281-34-8; (S)-2-(1-((9H-Purin-6-yl)Amino)Ethyl)-6-Fluoro-3-Phenylquinazolin-4(3H)-One

该化合物是磷酸三基酶(PI3K)路径的选择性抑制剂, 具体针对异族异族体(PI3K) , 主要是调查其在肿瘤学中的潜在治疗应用, 特别是治疗血液恶性肿瘤和某些固态肿瘤. Acalisib 展示了一种有利的药理动因特征, 允许口服治疗, 并展示了临床前和临床研究对于其抑制肿瘤生长和增强其他癌症疗法效果的希望.该化合物的特点是能够调节免疫反应, 使其在癌症和自动免疫性疾病研究中引起兴趣. 其化学结构包括有助于其选择性和能的特定功能组. 与许多调查药物一样, 正在进行的研究对于充分了解其有效性, 安全特征和各种病人群体的潜在副作用至关重要.

结构式图片

上下游产品

(S)-Tert-Butyl (1-(6-Fluoro-4-Oxo-3-Phenyl-3,4-Dihydroquinazolin-2-yl)Ethyl)Carbamate 1615253-60-5

合成工艺路线路线简述

    📜2-氨基-5-氟苯甲酸置于吡啶,盐酸,亚磷酸二苯酯,三乙胺,乙酰氯体系中,用 乙醇,水,甲苯,乙腈 作为反应溶剂,化学反应生成 Pi3Kδ抑制剂(Acalisib)
    参考文献:Process Methods For Phosphatidylinositol 3-Kindase Inhibitors
    标题:Process Methods For Phosphatidylinositol 3-Kindase Inhibitors
    摘要:本文公开了一种合成含喹唑啉酮类化合物的方法,这些化合物可能对癌症的治疗有用.此外,还公开了与这些方法相关的化合物中间体.

    海关参考信息

    专利信息


    专利号:US-2017283878-A1
    优先权日:2015-12-11
    标题:Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
    发明人:WONG CHI-HUEY; WU CHUNG-YI; CHEUNG SARAH K C; CHUANG PO-KAI; HSU TSUI-LING
    权利人:ACADEMIA SINICA
    摘要:The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for diagnostic and therapeutic uses.

    专利号:US-2025289827-A1
    优先权日:2022-12-02
    标 题:Morphic forms of a mutant braf degrader and methods of manufacture thereof
    发明人:YU ROBERT T; HE MINSHENG; SCHNADERBECK MATTHEW J; KREGER BRIDGET; POLLOCK ROY MACFARLANE; JIANG SIYI; LI MEIQI; CHEN BOLU; LU JIANNAN
    权利人:C4 THERAPEUTICS INC
    摘要:Advantageous isolated morphic forms of (3R)-3-[6-[2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]-6-fluorophenoxy]-4-oxoquinazolin-3-yl]-8-[2-[1-[3-(2,4-dioxo-1,3-diazinan-1-yl)-5-fluoro-1-methylindazol-6-yl]-4-hydroxypiperidin-4-yl]acetyl]-1-oxa-8-azaspiro[4.5]decane (Compound 1), which is a mutant BRAF degrader, and methods to prepare Compound 1 morphic forms for therapeutic applications are provided in the invention. The invention also provides improved methods for the synthesis of Compound 1, new pharmaceutical compositions comprising Compound 1, and new uses of Compound 1.

    专利号:WO-2024227949-A1
    优先权日:2023-05-04
    标 题:Screening and uses of glutamine synthetase modulators
    发明人:MARTINS GARCIA BRUNA; FARAH PERNAS LENA
    权利人:MAX PLANCK GESELLSCHAFT
    摘要:The present invention relates to an in vitro bioassay to identify glutamine synthetase activators and inhibitors on the basis of one or more glutamine markers such as citrate, a metabolite derived from the mevalonate pathway, a glutamine responsive mRNA or proteins, such as HMGCR or SREBP2. Disclosed herein are also glutamine synthetase activators and inhibitors identified by the inventive method for use to stimulate or inhibit the synthesis of a metabolite derived from the mevalonate pathway, such as cholesterol, and to treat a disease associated with deregulated levels of said metabolite, such as cancer.

    专利号:US-9567337-B2
    优先权日:2013-12-20
    标题 :Process methods for phosphatidylinositol 3-kinase inhibitors
    发明人:BREMNER STACY; EVARTS JERRY; SUJINO KEIKO; TRAN DUONG; VIZITIU DRAGOS
    权利人:GILEAD CALISTOGA LLC
    摘要:A process for the synthesis of quinazolinone containing compounds which may be useful for the treatment of cancer, is hereby disclosed. In addition, compound intermediates relating to these processes are also disclosed.

    专利号:US-2022411407-A1
    优先权日:2019-11-15
    标题:Aryl aminopyrimidines as dual mertk and tyro3 inhibitors and methods thereof
    发明人:WANG XIAODONG; ZHOU YUBAI; DING RANSHENG; KONG DEYU; FRYE STEPHEN
    权利人:UNIV NORTH CAROLINA CHAPEL HILL
    摘要:Aminopyrimidine containing compounds that inhibit both Mer tyrosine kinase (MerTK) activity and Tyro3 kinase activity are disclosed herein. Additionally disclosed are methods of synthesis and use of the aminopyrimidine containing compounds as anti-cancer agents, immunostimulatory and immunomodulatory agents, anti-platelet agents, anti-infective agents, and as adjunctive agents.

    专利号:WO-2023144235-A1
    优先权日:2022-01-27
    标 题 :Methods for monitoring and treating warburg effect in patients with pi3k-related disorders
    发明人:CANAUD GUILLAUME; LADRAA SOPHIA
    权利人:INST NAT SANTE RECH MED; ASSIST PUBLIQUE HOPITAUX PARIS APHP; CENTRE NAT RECH SCIENT; UNIV PARIS CITE
    摘要:Using a unique tool of PROS, they demonstrate that PIK3CA mutation leads to GLUT4 membrane accumulation with a negative feedback loop on insulin secretion, a burst of liver IGFBP1 synthesis with IGF1 sequestration and low circulating levels. They further show that AKT2 drives a large part of the phenotype. In addition, they demonstrate for the first time that a single PIK3CA mutation induces metabolic reprogramming with the Warburg effect and protein and lipid synthesis—hallmarks of cancer cells—in vitro, in vivo and in patients. They finally show that alpelisib, an approved PIK3CA inhibitor in oncology, is efficient at preventing and improving PIK3CA-adipose tissue overgrowth and reversing metabolomic anomalies in both animal models and patients. Accordingly, the present invention relates to an in vitro method for monitoring the efficiency of a PI3K inhibitor treatment in a subject in need thereof comprising the step of determining the level of at least one metabolite selected in the group consisting of cis-aconitate, succinic acid, 5-methylcytosine, acetyl-carnitine, acetyl-lysine, argininosuccinate, betaine, butyric acid, carnitine, creatine, glucose, glycine, hexanoyl-carnitine, L-fucose, lactate, L-dihydroorotic acid, linolenic acid, nicotinamide N-oxide, palmitoyl-carnitine, panthotenate, pyruvate, quinolinic acid, tryptophan, urate, in a biological sample obtained from the subject.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Kater AP, Tonino SH, Spiering M, Chamuleau MED, Liu R, Adewoye AH, Gao J, Dreiling L, Xin Y, Doorduijn JK, Kersten MJ; HOVON Lunenburg Lymphoma Phase I/II Consortium. Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies. Blood Cancer J. 2018 Feb 12;8(2):16. doi: 10.1038/s41408-018-0055-x.
    2: Lopez-Guadamillas E, Muñoz-Martin M, Martinez S, Pastor J, Fernandez-Marcos PJ, Serrano M. PI3Kα inhibition reduces obesity in mice. Aging (Albany NY). 2016 Nov 4;8(11):2747-2753. doi: 10.18632/aging.101075.

    合成参考文献


    参考文献:10.1124/mol.119.115964
    摘要:Lee TD, Lee OW, Brimacombe KR, Chen L, Guha R, Lusvarghi S, Tebase BG, Klumpp-Thomas C, Robey RW, Ambudkar SV, Shen M, Gottesman MM, Hall MD. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular Pharmacology. 2019 Nov;96(5):629–40. doi: 10.1124/mol.119.115964.
    参考文献:10.1134/s1070428024601997
    摘要:Suryanarayana NS, Sridhar C, Bindu GH. Design and Synthesis of 1,3,4-Oxadiazole–Quinazolinone Hybrids, Evaluation of Their Anticancer and Antimicrobial Activities, and Docking Studies. Russ J Org Chem. 2025 Jan;61(1):92–104. doi: 10.1134/s1070428024601997.
    参考文献:10.1007/s12032-021-01462-5
    摘要:Singh P, Kumar V, Gupta SK, Kumari G, Verma M. Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review. Med Oncol. 2021 Jan 16;38(1):10. doi: 10.1007/s12032-021-01462-5.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知